RESUMEN
OBJECTIVES: To observe the effect of electroacupuncture (EA) on the Wnt/ß-catenin signaling pathway and epithelial-mesenchymal transition (EMT)-related proteins in rats with intrauterine adhesions (IUA), so as to explore the possible mechanisms of EA in repairing endometrial damage in IUA. METHODS: Female SD rats were randomly divided into blank, model, EA, and ICG-001 groups, with 10 rats in each group. The IUA model was established by using mechanical scraping combined with lipopolysaccharide infection for double injury. In the EA group, "Guanyuan" (CV4) was needled and EA (2 Hz/15 Hz, 1-2 mA) was applied to "Zusanli" (ST36) and "Sanyinjiao"(SP6) on both sides. In the ICG-001 group, ICG-001 (5 mg/kg), the inhibitor of ß-catenin was intraperitoneally injected. After intervention, samples were taken from 5 rats in each group, and uterine endometrium morphology, endometrial thickness, and gland counts were observed using HE staining. Masson staining was used to assess the degree of fibrosis in the endometrial tissue. Immunohistochemistry was used to detect the positive expression of transforming growth factor ß1 (TGF-ß1), α-smooth muscle actin (α-SMA), fibronectin (FN), connective tissue growth factor (CTGF), type I collagen (Col- â ), glycogen synthase kinase-3ß (GSK-3ß), ß-catenin, E-cadherin, N-cadherin, and Vimentin in the endometrial tissue. Western blot was used to detect the relative expression of GSK-3ß, ß-catenin, E-cadherin, N-cadherin, and Vimentin proteins in the endometrial tissue. Another 5 rats from each group were placed in cages with male rats after intervention to record the number of embryo implantations. RESULTS: Necrosis and loss of endometrial tissue in the model group observed after HE staining were alleviated in the EA group, better than those in the ICG-001 group. Compared with the blank group, the numbers of glands and endometrial thickness in the uterine endometrial tissue, relative expression and positive expression of E-cadherin and GSK-3ß proteins in the uterine endometrial tissue, and embryo implantation numbers were reduced(P<0.000 1, P<0.001, P<0.01) in the model group, while fibrosis area ratio in the uterine endometrial tissue, TGF- ß 1, α -SMA, FN, CTGF, Col- â positive expressions, N-cadherin, Vimentin, and ß-catenin proteins expression and positive expression were increased(P<0.000 1, P<0.001, P<0.01). Compared with the model group, the number of glands and endometrial thickness, E-cadherin and GSK-3ß proteins expression and positive expression, and embryo implantation numbers were increased (P<0.001, P<0.05, P<0.01) in the EA and ICG-001 groups, while the fibrosis area ratio in the uterine endometrial tissue, TGF-ß1, α-SMA, FN, CTGF, Col- â positive expression, and N-cadherin, Vimentin, and ß-catenin proteins expression and positive expression were decreased(P<0.001, P<0.01, P<0.05). Compared with the EA group, the differences of the above-mentioned indicators in the ICG-001 group were not statistically significant. CONCLUSIONS: EA may reverse the EMT process and reduce the degree of fibrosis in endometrial tissue by inhibiting the Wnt/ß-catenin signaling pathway, thereby promoting the repair of endometrial damage in IUA.
Asunto(s)
Electroacupuntura , Endometrio , Transición Epitelial-Mesenquimal , Fibrosis , Ratas Sprague-Dawley , Vía de Señalización Wnt , beta Catenina , Animales , Femenino , Ratas , Humanos , beta Catenina/metabolismo , beta Catenina/genética , Endometrio/metabolismo , Fibrosis/terapia , Fibrosis/genética , Adherencias Tisulares/terapia , Adherencias Tisulares/metabolismo , Adherencias Tisulares/genética , Enfermedades Uterinas/terapia , Enfermedades Uterinas/metabolismo , Enfermedades Uterinas/genética , Cadherinas/metabolismo , Cadherinas/genética , Puntos de Acupuntura , Útero/metabolismoRESUMEN
Fibrosis is a pathological process, that could result in permanent scarring and impairment of the physiological function of the affected organ; this condition which is categorized under the term organ failure could affect various organs in different situations. The involvement of the major organs, such as the lungs, liver, kidney, heart, and skin, is associated with a high rate of morbidity and mortality across the world. Fibrotic disorders encompass a broad range of complications and could be traced to various illnesses and impairments; these could range from simple skin scars with beauty issues to severe rheumatologic or inflammatory disorders such as systemic sclerosis as well as idiopathic pulmonary fibrosis. Besides, the overactivation of immune responses during any inflammatory condition causing tissue damage could contribute to the pathogenic fibrotic events accompanying the healing response; for instance, the inflammation resulting from tissue engraftment could cause the formation of fibrotic scars in the grafted tissue, even in cases where the immune system deals with hard to clear infections, fibrotic scars could follow and cause severe adverse effects. A good example of such a complication is post-Covid19 lung fibrosis which could impair the life of the affected individuals with extensive lung involvement. However, effective therapies that halt or slow down the progression of fibrosis are missing in the current clinical settings. Considering the immunomodulatory and regenerative potential of distinct stem cell types, their application as an anti-fibrotic agent, capable of attenuating tissue fibrosis has been investigated by many researchers. Although the majority of the studies addressing the anti-fibrotic effects of stem cells indicated their potent capabilities, the underlying mechanisms, and pathways by which these cells could impact fibrotic processes remain poorly understood. Here, we first, review the properties of various stem cell types utilized so far as anti-fibrotic treatments and discuss the challenges and limitations associated with their applications in clinical settings; then, we will summarize the general and organ-specific mechanisms and pathways contributing to tissue fibrosis; finally, we will describe the mechanisms and pathways considered to be employed by distinct stem cell types for exerting anti-fibrotic events.
Asunto(s)
Fibrosis , Humanos , Fibrosis/terapia , Trasplante de Células Madre , Esclerodermia Sistémica/terapia , Esclerodermia Sistémica/patología , Animales , COVID-19/terapia , COVID-19/patología , COVID-19/inmunologíaRESUMEN
BACKGROUND: Diabetic cardiomyopathy (DCM) is a serious health-threatening complication of diabetes mellitus characterized by myocardial fibrosis and abnormal cardiac function. Human umbilical cord mesenchymal stromal cells (hUC-MSCs) are a potential therapeutic tool for DCM and myocardial fibrosis via mechanisms such as the regulation of microRNA (miRNA) expression and inflammation. It remains unclear, however, whether hUC-MSC therapy has beneficial effects on cardiac function following different durations of diabetes and which mechanistic aspects of DCM are modulated by hUC-MSC administration at different stages of its development. This study aimed to investigate the therapeutic effects of intravenous administration of hUC-MSCs on DCM following different durations of hyperglycemia in an experimental male model of diabetes and to determine the effects on expression of candidate miRNAs, target mRNA and inflammatory mediators. METHODS: A male mouse model of diabetes was induced by multiple low-dose streptozotocin injections. The effects on severity of DCM of intravenous injections of hUC-MSCs and saline two weeks previously were compared at 10 and 18 weeks after diabetes induction. At both time-points, biochemical assays, echocardiography, histopathology, polymerase chain reaction (PCR), immunohistochemistry and enzyme-linked immunosorbent assays (ELISA) were used to analyze blood glucose, body weight, cardiac structure and function, degree of myocardial fibrosis and expression of fibrosis-related mRNA, miRNA and inflammatory mediators. RESULTS: Saline-treated diabetic male mice had impaired cardiac function and increased cardiac fibrosis after 10 and 18 weeks of diabetes. At both time-points, cardiac dysfunction and fibrosis were improved in hUC-MSC-treated mice. Pro-fibrotic indicators (α-SMA, collagen I, collagen III, Smad3, Smad4) were reduced and anti-fibrotic mediators (FGF-1, miRNA-133a) were increased in hearts of diabetic animals receiving hUC-MSCs compared to saline. Increased blood levels of pro-inflammatory cytokines (IL-6, TNF, IL-1ß) and increased cardiac expression of IL-6 were also observed in saline-treated mice and were reduced by hUC-MSCs at both time-points, but to a lesser degree at 18 weeks. CONCLUSION: Intravenous injection of hUC-MSCs ameliorated key functional and structural features of DCM in male mice with diabetes of shorter and longer duration. Mechanistically, these effects were associated with restoration of intra-myocardial expression of miRNA-133a and its target mRNA COL1AI as well as suppression of systemic and localized inflammatory mediators.
Asunto(s)
Diabetes Mellitus Experimental , Cardiomiopatías Diabéticas , Fibrosis , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas , MicroARNs , Miocardio , Cordón Umbilical , Animales , Humanos , Masculino , Ratones , Diabetes Mellitus Experimental/terapia , Diabetes Mellitus Experimental/metabolismo , Cardiomiopatías Diabéticas/terapia , Cardiomiopatías Diabéticas/metabolismo , Cardiomiopatías Diabéticas/patología , Cardiomiopatías Diabéticas/genética , Fibrosis/terapia , Trasplante de Células Madre Mesenquimatosas/métodos , Células Madre Mesenquimatosas/metabolismo , Ratones Endogámicos C57BL , MicroARNs/genética , MicroARNs/metabolismo , Miocardio/metabolismo , Miocardio/patología , Cordón Umbilical/citología , Cordón Umbilical/metabolismoRESUMEN
PURPOSE: Corneal fibrosis and neovascularization (CNV) after ocular trauma impairs vision. This study tested therapeutic potential of tissue-targeted adeno-associated virus5 (AAV5) mediated decorin (DCN) and pigment epithelium-derived factor (PEDF) combination genes in vivo. METHODS: Corneal fibrosis and CNV were induced in New Zealand White rabbits via chemical trauma. Gene therapy in stroma was delivered 30-min after chemical-trauma via topical AAV5-DCN and AAV5-PEDF application using a cloning cylinder. Clinical eye examinations and multimodal imaging in live rabbits were performed periodically and corneal tissues were collected 9-day and 15-day post euthanasia. Histological, cellular, and molecular and apoptosis assays were used for efficacy, tolerability, and mechanistic studies. RESULTS: The AAV5-DCN and AAV5-PEDF combination gene therapy significantly reduced corneal fibrosis (p < 0.01 or p < 0.001) and CNV (p < 0.001) in therapy-given (chemical-trauma and AAV5-DCN + AAV5-PEDF) rabbit eyes compared to the no-therapy given eyes (chemical-trauma and AAV5-naked vector). Histopathological analyses demonstrated significantly reduced fibrotic α-smooth muscle actin and endothelial lectin expression in therapy-given corneas compared to no-therapy corneas on day-9 (p < 0.001) and day-15 (p < 0.001). Further, therapy-given corneas showed significantly increased Fas-ligand mRNA levels (p < 0.001) and apoptotic cell death in neovessels (p < 0.001) compared to no-therapy corneas. AAV5 delivered 2.69 × 107 copies of DCN and 2.31 × 107 copies of PEDF genes per µg of DNA. AAV5 vector and delivered DCN and PEDF genes found tolerable to the rabbit eyes and caused no significant toxicity to the cornea. CONCLUSION: The combination AAV5-DCN and AAV5-PEDF topical gene therapy effectively reduces corneal fibrosis and CNV with high tolerability in vivo in rabbits. Additional studies are warranted.
Asunto(s)
Neovascularización de la Córnea , Fibrosis , Terapia Genética , Factores de Crecimiento Nervioso , Serpinas , Animales , Conejos , Córnea/patología , Córnea/metabolismo , Neovascularización de la Córnea/terapia , Neovascularización de la Córnea/genética , Neovascularización de la Córnea/patología , Neovascularización de la Córnea/metabolismo , Decorina/genética , Decorina/metabolismo , Dependovirus/genética , Modelos Animales de Enfermedad , Proteínas del Ojo/genética , Proteínas del Ojo/metabolismo , Fibrosis/terapia , Terapia Genética/métodos , Vectores Genéticos , Factores de Crecimiento Nervioso/genética , Factores de Crecimiento Nervioso/metabolismo , Serpinas/genética , Serpinas/metabolismoRESUMEN
ABSTRACT A 27-year-old healthy man with a history of bilateral photorefractive keratectomy (PRK) enhancement after femtosecond laser in situ keratomileusis (LASIK) presented with decreased uncorrected distance visual acuity (UDVA) of 20/125 in the right eye (OD) and 20/300 in the left eye (OS) six months after PRK. Examination revealed bilateral dense subepithelial opacities. Both eyes (OU) were treated with superficial keratectomy combined with phototherapeutic keratectomy (PTK) and adjunctive application of mitomycin C 0.02%. At three months follow up UDVA was 20/30 OD and 20/25 OS. Superficial keratectomy combined with PTK seems to be a safe and efficient technique for treatment of dense subepithelial scar formation following PRK enhancement after LASIK.
RESUMO Um homem saudável de 27 anos de idade com história de aprimoramento com ceratectomia fotorrefrativa (PRK) bilateral, após Ceratomileuse Assistida por Excimer Laser In Situ (LASIK) com laser de femtossegundos, apresentou diminuição da acuidade visual à distância não corrigida (AVNC) de 20/125 no olho direito (OD) e 20/300 no olho esquerdo (OE) seis meses após PRK. O exame revelou opacidades subepiteliais densas bilaterais. Ambos os olhos (AO) foram tratados com queratectomia superficial combinada com ceratectomia fototerapêutica (PTK) e aplicação adjuvante de mitomicina C a 0,02%. Aos três meses de acompanhamento, o AVNC foi de 20/30 OD e 20/25 OE. A ceratectomia superficial combinada com PTK parece ser uma técnica segura e eficiente para o tratamento da formação densa de cicatrizes subepiteliais após o aprimoramento com PRK pós-LASIK.
Asunto(s)
Humanos , Masculino , Adulto , Fibrosis/terapia , Queratectomía Fotorrefractiva/efectos adversos , Cicatrización de Heridas , Fibrosis/etiología , Agudeza Visual , Mitomicina/administración & dosificación , Queratectomía Fotorrefractiva/métodos , Opacidad de la Córnea/diagnóstico , Opacidad de la Córnea/etiología , Topografía de la Córnea , Queratomileusis por Láser In Situ , Desbridamiento , Cirugía Laser de Córnea , Microscopía con Lámpara de Hendidura , Miopía/cirugíaRESUMEN
Objective. )e aim of the present study was to report the physiological stimulation of the synthesis of preelastic fibers in the dermis of a patient with fibrosis. Design. A clinical study was conducted involving the analysis of histological changes in preelastic fibers following treatment for stage II primary lymphedema for the clinical reversal of lymphedema and fibrosis. Setting. University Hospital of the São Jose do Rio Preto of School of Medicine in 2020. Participant was a 67-year-old male patient with late-onset primary lymphedema diagnosed 12 years earlier. Intervention is the lymphatic stimulation using the Godoy method adapted to the treatment of fibrosis. Main outcomes and measures are biopsies before and after treatment. Ten randomly selected histological fields were evaluated using the multipoint morphometric method. )e values with this method are relative and expressed as percentages. Statistical analysis was performed with the t-test, considering a 95% significance level. Results. A visible, significant difference in the percentage of preelastic fibers was found between the preintervention and postintervention slides, which were confirmed by the microscopic evaluation and quantification (4.95 ± 0.64% and 14.70 ± 1.06%, respectively). Conclusion. )e physiological stimulation of the lymphatic system using a specific method resulted in the clinical reduction of fibrosis, the return of the elasticity of the skin, and the stimulation of the synthesis of preelastic fibers.
Asunto(s)
Humanos , Masculino , Anciano , Fibrosis/terapia , Linfedema/terapia , DermisRESUMEN
En las últimas décadas, los cambios en el estilo de vida pro-vocaron un incremento en la prevalencia del síndrome meta-bólico y que la enfermedad por hígado graso no alcohólico (nonalcoholic fatty liver disease, NAFLD sus siglas en inglés) se convierta en la enfermedad hepática crónica más fre-cuente en todo el mundo. Los componentes del síndrome metabólico no son sólo altamente prevalentes en pacientes con hígado graso no alcohólico, sino que a la vez aumentan el riesgo de desarrollarlo. Esta relación bidireccional ha sido claramente establecida. Asimismo se considera que NAFLD podría ser el componente hepático del síndrome metabólico. Aunque NAFLD se considera principalmente una enfermedad benigna, puede progresar a fibrosis hepática grave y carcino-ma hepatocelular (CHC), incluso se encontraría este último en hígados no cirróticos. El objetivo de esta revisión es determinar los procesos fisio-patológicos comunes a estas entidades, cuáles son las estra-tegias diagnósticas recomendadas y cuáles las intervenciones terapéuticas actualmente aprobadas.
Asunto(s)
Humanos , Masculino , Femenino , Carcinoma Hepatocelular/etiología , Síndrome Metabólico/etiología , Enfermedad del Hígado Graso no Alcohólico/complicaciones , Neoplasias Hepáticas/etiología , Fibrosis/etiología , Fibrosis/fisiopatología , Fibrosis/terapia , Factores de Riesgo , Carcinoma Hepatocelular/fisiopatología , Carcinoma Hepatocelular/terapia , Carcinoma Hepatocelular/diagnóstico por imagen , Síndrome Metabólico/diagnóstico , Síndrome Metabólico/fisiopatología , Síndrome Metabólico/terapia , Diabetes Mellitus/etiología , Diabetes Mellitus/fisiopatología , Diabetes Mellitus/terapia , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Enfermedad del Hígado Graso no Alcohólico/fisiopatología , Enfermedad del Hígado Graso no Alcohólico/terapia , Neoplasias Hepáticas/fisiopatología , Neoplasias Hepáticas/terapia , Neoplasias Hepáticas/diagnóstico por imagenRESUMEN
BACKGROUND Fibrosis in the peripheral nerve is the end stage of leprous neuropathy and the cause of the resulting permanent neural function impairments. Preventive measures to avoid this irreversible pathological state are a relief strategy for leprosy sufferers. OBJECTIVES The present study describes the frequency of fibrosis along with its characterisation and pathogenic development. METHODS Six-hundred-and-thirteen nerve samples were sorted from 278 neural leprosy (NL) and 335 non-leprosy neuropathy patients (ON). The total number of samples was histologically examined by routine staining methods (haematoxylin-eosin, Wade staining and Gomori's trichrome) and fibrosis was evaluated via semi-quantitative estimation. FINDINGS Fibrosis was most frequent in the NL group (33% against 0.4% in ON) while fibrosis in association with endoneurial microfasciculation was found in 38 (41.3%) of the NL samples in the examination of semithin sections. Pericytic activation in the perivascular environment was confirmed to be the source of the fibroblasts and perineurial cells delimiting microfascicles. End-stage fibrosis in leprosy displays an arrangement of microfascicles devoid of neural components (i.e., Schwann cells and axons) lined by an intermediate phenotype of fibroblastic-perineurial cells filled with bundles of collagen fibres. MAIN CONCLUSIONS The present study underscores that fibrosis is frequently the severe end stage of neural leprosy NL pathogeny after analysing the notably distinct development of fibrosis within the neural environment.
Asunto(s)
Humanos , Fibrosis/diagnóstico , Fibrosis/terapia , Lepra Tuberculoide/diagnóstico , Lepra Tuberculoide/prevención & controlRESUMEN
Objetivo: Determinar el efecto del plasma rico en plaquetas y factores de crecimiento sobre la regeneración y la reducción del dolor en discopatía degenerativa. Material y método: Revisión sistemática de la literatura. Se siguió las recomendaciones de la colaboración Cochrane expuestas en el Cochrane Hand book for Systematic Reviews of interventions. Se incluyeron ensayos clínicos aleatorizados fases preclínicas y clínicas donde evaluaban el efecto del plasma rico en plaquetas o factores de crecimiento sobre la discopatía degenerativa entre el 1 de septiembre de 2013 y el 30 de septiembre de 2014, publicados en PubMed, MEDLINE y LILACS. Resultados: En la búsqueda inicial se identificaron 11 artículos, de los cuales 3 cumplieron los criterios de selección determinados para esta revisión. Se realizó estrategia de búsqueda donde se revisaron las citas relacionadas de los tres artículos principales. De éstos, sólo 6 cumplieron los criterios de selección. Se incluyeron dos artículos más que arrojó la búsqueda en google académico, quedando un total de 10 estudios para el análisis final. En esta revisión, nosotros incluimos en la búsqueda de no sólo aquellos estudios realizados in vitro, sino además aquellos estudios en modelos murinos y estudio realizado en humanos. De estos estudios, la mayor parte de ellos fueron realizados in vitro (6), en modelos animales (2) y en humanos (2). En este estudio se seleccionaron sólo aquellos estudios donde fue evaluado el PRP y/o los factores de crecimiento sobre las células o tejidos del disco intervertebral. Para poder conocer el efecto que estas sustancias, tienen que ser evaluadas en estudios tanto preclínicos como clínicos. Todos los estudios analizados coincidieron sobre el efecto antiinflamatorio, reparador, proliferador e incluso en la mejoría del dolor de la discopatía vertebral. Conclusiones: Los resultados de los estudios muestra el efecto antiinflamatorio, reparador, proliferador e incluso en la mejoría del dolor de la discopatía vertebral. En ninguno de ellos se mencionó si este aumento de la síntesis de la matriz conllevaría a una mayor fibrosis del tejido y mayor deterioro, por lo que los estudios en animales o en humanos deberían enfocarse a evaluar un seguimiento mayor para poder evaluar los efectos tardíos de la terapia. Por lo tanto, podemos concluir que los puntos de enfoque de la investigación actual debe apuntar hacia entender más el mecanismo de la degeneración discal conjuntamente con los beneficios del PRP en tratarla (AU)
Objective: To determine the effect of platelet-rich plasma and growth factors on regeneration and reduction of pain in degenerative disc disease. Methods: Systematic review of the literature. The recommendations of the Cochrane Collaboration Cochrane outlined in the Handbook for Systematic Reviews of interventions was followed; randomized clinical trials preclinical and clinical phases which evaluated the effect of platelet-rich plasma or growth factors for degenerative disc disease between september 1/2013 to september 30/2014, published in PubMed, MEDLINE and LILACS were included. Results: The initial search 11 items of which 3 met the selection criteria determined for this review were identified. Search strategy where citations related to the three main articles were reviewed was conducted. Of these only 6 met the selection criteria. Threw two articles in academic google search, leaving a total of 10 studies were included in the final analysis. In this review we include in the search not only those studies in vitro but also those studies in murine models and human study. From these studies, most of them were done in vitro (6), in animal models (2) and in humans (2). In those studies where this study was evaluated PRP and growth factors on cells or tissues of the intervertebral disc is selected alone. To know the effect these substances have to be evaluated in both preclinical and clinical studies. All studies reviewed agreed on the anti-inflammatory effect, repair, and even proliferator improvement in pain, vertebral discopathy. Conclusions: The results of studies showing the anti-inflammatory effect, repair, and even proliferator improvement in pain, vertebral discopathy. None of them mention whether this increased matrix synthesis would lead to greater tissue fibrosis and further deterioration, so that studies in animals or humans should focus on evaluating increased monitoring, to assess late effects of therapy. Therefore we can conclude that the focus points of the present investigation should point to more understand the mechanism of disc degeneration together with the benefits of PRP to treat it (AU)
Asunto(s)
Humanos , Masculino , Femenino , Plasma Rico en Plaquetas , Péptidos y Proteínas de Señalización Intercelular/farmacocinética , Dolor Crónico/epidemiología , Dolor Crónico/prevención & control , Medicina Basada en la Evidencia/métodos , Dolor de la Región Lumbar/epidemiología , Dolor de la Región Lumbar/terapia , Disco Intervertebral , Disco Intervertebral/patología , Disco Intervertebral , Trastornos Heredodegenerativos del Sistema Nervioso/complicaciones , Trastornos Heredodegenerativos del Sistema Nervioso/terapia , Fibrosis/complicaciones , Fibrosis/terapiaRESUMEN
OBJETIVO: Determinar si el uso de Cefazolina como profilaxis antibiótica produce una disminución significativa de las infecciones en pacientes cirróticos con sangrado digestivo, comparado con Ciprofloxacino. Material y MétodoS: Ensayo Clínico aleatorizado. Se incluyeron a pacientes cirróticos mayores de 18 años, con sangrado digestivo, que ingresaron entre Julio del 2008 a julio del 2010 a la Unidad de hemorragia Digestiva del HNERM, sin evidencia clínica ni de laboratorio de infección al momento del ingreso y que no hubieran recibido tratamiento antibióticolas últimas 2 semanas. A un grupo se le administró Ciprofloxacino 200 mg bid EV y al otro Cefazolina 1 g tid EV.x 7 dias. RESULTADOS: Fueron incluidos 98 pacientes, 53 pacientes en el grupo de Cefazolina y 45 en el grupo de Ciprofloxacino. El promedio de edad fue 66 +/- 10 años, 61 % varones; 59,2 % tuvieron ascitis, la frecuencia de infecciones en la población total fue de 14,3% (14/98). El resangrado fue 8,1% y la mortalidad general 4,1%. No hubo diferencias significativas entre los grupos en relación a edad, sexo, estadio Child, ascitis, encefalopatía, ni en promedio de Bilirrubina, TP, Creatinina y niveles de Albúmina. El grupo que usó Cefazolina tuvo 11,3 % de infecciones, comparado con el 17,8% de infecciones en el grupo que recibió Ciprofloxacino (p= 0,398) IC 95%. Cuando se excluyó del análisis los pacientes cirróticos Child A y aquellos sin ascitis, se encontró: 22,2 % de infecciones en el grupo de cefazolina y 26,9 % en el grupo de Ciprofloxacino (p=0,757 IC 95%).
AIM: To determine if prophylaxis with cefazolin produces a significant reduction in infections in cirrhotic patients with gastrointestinal bleeding when compared with ciprofloxacin. METHODS: Randomized clinical trial. Patients 18 years or older with diagnosis of cirrhosis, gastrointestinal bleeding and no clinical or laboratory evidence of infection who were admitted to the gastrointestinal bleeding unit of HNERM between July 2008 and July 2010 were included. Patients were allocated to receive either i.v. ciprofloxacin 200 mg bid or i.v. cefazolin 1 gm tid for 7 days. RESULTS: 98 patients were included, 53 in the cefazolin group and 45 in the ciprofloxacinone. Age average was 66 +/- 10 years, 61% were male, 59,2% had ascites. Overall rate of infections was 14,3% (14/98). Rebleeding rate was 8,1% and mortality 4,1%. There were nodifferences in age, sex, Child Pugh score, ascites, hepatic encephalopathy nor in billirubin, albumin, PT and creatinine levels between the study groups. Infection rate in the cefazolin groups was 11,3% while in the ciprofloxacin one 17,8% (p=0,398). When Child-Pugh A and patients without ascites were excluded of the analysis, the cefalozin group had 22,2% of infections and 26,9% in the ciprofloxacin one (p=0,757).
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Cefazolina/uso terapéutico , Ciprofloxacina/uso terapéutico , Fibrosis/terapia , Hemorragia Gastrointestinal/terapiaRESUMEN
En tiempos recientes, la miocardiopatía cirrótica ha pasado a ser considerada una nueva entidad clínica. El reconocimiento de cambios leves en la estructura cardíaca que pueden ser detectados incluso en las etapas iniciales de la cirrosis preascítica ha contribuido a una mejor comprensión de los trastornos cardiovasculares que se observan a medida que progresa la enfermedad. Se han categorizado cambios cardíacos estructurales y se diagnóstica, con frecuencia, la disfunción diastólica. La cirrosis descompensada se caracteriza por una disminución de la presión sanguínea y de la resistencia vascular periférica, y un aumento del gasto cardíaco y de la frecuencia cardíaca, los cuales se producen en un escenario de circulación hiperdinámica favorecida por la expansión del volumen total sanguíneo, la sobrecarga circulatoria y la hiperactividad de los sistemas endógenos vasoactivos. La vasodilatación periférica evita la insuficiencia cardíaca. Recientemente se ha reconocido la existencia de una menor respuesta cardíaca en situaciones de estrés como son los cambios en las condiciones de la carga cardíaca en presencia de un mayor deterioro de la función hepática, tales como la ascitis refractaria, el síndrome hepatorrenal, la peritonitis bacteriana espontánea y la hemorragia de várices esofágicas. Ante la disponibilidad de intervenciones terapéuticas (paracentesis, comunicación portosistémica intrahepática transyugular, comunicación venosa peritoneal, trasplante hepático) utilizadas actualmente para manejar las complicaciones potencialmente mortalesen las formas más avanzadas de cirrosis, el conocimiento del impacto que tienen en la función cardiovascular es de suma importancia. Se encuentran en progreso las intervenciones terapéuticas dirigidas a prevenir y manejar el deterioro cardiovascular.(AU)
Asunto(s)
Fibrosis/complicaciones , Fibrosis/terapia , Cardiomiopatías/diagnóstico , Cardiomiopatías/etiología , Cardiomiopatías/terapia , Ascitis/terapiaRESUMEN
En tiempos recientes, la miocardiopatía cirrótica ha pasado a ser considerada una nueva entidad clínica. El reconocimiento de cambios leves en la estructura cardíaca que pueden ser detectados incluso en las etapas iniciales de la cirrosis preascítica ha contribuido a una mejor comprensión de los trastornos cardiovasculares que se observan a medida que progresa la enfermedad. Se han categorizado cambios cardíacos estructurales y se diagnóstica, con frecuencia, la disfunción diastólica. La cirrosis descompensada se caracteriza por una disminución de la presión sanguínea y de la resistencia vascular periférica, y un aumento del gasto cardíaco y de la frecuencia cardíaca, los cuales se producen en un escenario de circulación hiperdinámica favorecida por la expansión del volumen total sanguíneo, la sobrecarga circulatoria y la hiperactividad de los sistemas endógenos vasoactivos. La vasodilatación periférica evita la insuficiencia cardíaca. Recientemente se ha reconocido la existencia de una menor respuesta cardíaca en situaciones de estrés como son los cambios en las condiciones de la carga cardíaca en presencia de un mayor deterioro de la función hepática, tales como la ascitis refractaria, el síndrome hepatorrenal, la peritonitis bacteriana espontánea y la hemorragia de várices esofágicas. Ante la disponibilidad de intervenciones terapéuticas (paracentesis, comunicación portosistémica intrahepática transyugular, comunicación venosa peritoneal, trasplante hepático) utilizadas actualmente para manejar las complicaciones potencialmente mortalesen las formas más avanzadas de cirrosis, el conocimiento del impacto que tienen en la función cardiovascular es de suma importancia. Se encuentran en progreso las intervenciones terapéuticas dirigidas a prevenir y manejar el deterioro cardiovascular.
Asunto(s)
Ascitis/terapia , Cardiomiopatías/diagnóstico , Cardiomiopatías/etiología , Cardiomiopatías/terapia , Fibrosis/complicaciones , Fibrosis/terapiaRESUMEN
Objective. The authors conducted a study to compare the effectiveness of Oxiplex and Gore-tex in preventing postlaminectomy peridural fibrosis in rats. Peridural fibrosis is a common cause of pain in patients undergoing spinal surgery. To prevent scar formation numerous materials and methods have been employed such as non steroidal anti-inflammatory drugs (NSAIDs), Gelfoam, Oxiplex, Gore-tex, carboxymethil cellulose, Adcon-L, autogenous adipose grefting, mitomisin, and radiotherapy have been investigating for a long time, but only moderate success has been obtained. Methods. Laminectomies were performed at the fourth lumbar vertebra (L-4) in 30 rats. Oxiplex or Gore-Tex was applied over the dura mater with the aim to perform a blinded evaluation of their effects. In the control group, only a L-4 laminectomy was performed. Animals were sacrificed 28 days after the surgical procedure. The extent of peridural fibrosis was evaluated on spine specimens by histological analysis. Results. Both groups of animals treated with either Oxiplex or Gore-Tex showed a significant reduction in the degree of peridural fibrosis as compared to the control group. However no significant difference in the prevention of peridural fibrosis was observed between the Oxiplex and Gore-Tex groups. Conclusions. This experimental model has shown that Oxiplex and Gore-Tex are effective methods to prevent peridural fibrosis and dural adhesions at the postlaminectomy áreas (AU)
Objetivo. Los autores realizaron un estudio para comparar la eficacia de Oxiplex y Gore-tex en la prevención de fibrosis peridural tras laminectomías en ratas. La fibrosis peridural es una causa común de dolor en pacientes sometidos a cirugía de la columna vertebral. Para evitar la formación de cicatriz, se han empleado numerosos materiales y métodos como los antiinflamatorios no esteroideos (AINE), Gelfoam, Oxiplex, Gore-tex, carboxymethil celulosa, Adcon-L, injertos de grasa antóloga, mitomicina o la radioterapia, pero sólo se ha obtenido resultados exitosos en pocas ocasiones. Métodos. Se realizaron laminectomías en la cuarta vértebra lumbar (L-4) en 30 ratas. Se aplicaron Oxiplex o Gore-Tex sobre la duramadre con el objetivo de realizar una evaluación ciega de sus efectos. En el grupo control, sólo se realizó la laminectomía L4. Los animales fueron sacrificados 28 días después de la intervención quirúrgica. El grado de fibrosis peridural se evaluó sobre la columna vertebral de especímenes por análisis histológico. Resultados. Ambos grupos de animales tratados con Oxiplex o Gore-Tex mostraron una reducción significativa en el grado de fibrosis peridural en comparación con el grupo control. Sin embargo, ninguna diferencia significativa en la prevención de la fibrosis peridural se observó entre los grupos de Oxiplex y Gore-Tex. Conclusiones. Este modelo experimental ha demostrado que Oxiplex y Gore-Tex son métodos eficaces para prevenir la fibrosis peridural y adherencias en la duramadre tras laminectomías (AU)
Asunto(s)
Animales , Ratas , Fibrosis/congénito , Fibrosis/veterinaria , Anestesia Epidural/métodos , Laminectomía/métodos , Laminectomía/normas , Duramadre/anomalías , Duramadre/lesiones , Traumatismos Vertebrales/complicaciones , Preparaciones Farmacéuticas/química , Fibrosis/genética , Fibrosis/terapia , Anestesia Epidural , Laminectomía , Laminectomía/veterinaria , Duramadre/metabolismo , Duramadre/patología , Traumatismos Vertebrales/patología , Preparaciones Farmacéuticas/análisisRESUMEN
O presente estudo objetivou avaliar a drenagem linfática como forma coadjuvante de tratamento, em uma paciente idosa com dermatofibrose, flebite de membro inferior e queixa de dores na perna, localizada em região pós-flebítica. Foi realizado tratamento clínico inicial por três meses com drogas venotônicas (diosmin), anti-inflamatórios, analgésicos e repouso, porém com pouca melhora clínica. Foi, então, associada ao tratamento clínico, a drenagem linfática manual e mecânica. Os resultados obtidos incluíram a redução dos sintomas dolorosos e da hiperpigmentação do local acometido. Este trabalho sugere que a drenagem linfática obteve melhora do quadro clínico de paciente portadora de dermatofibrose, sugerindo novas pesquisas para caracterização mais específica dessa abordagem.
This study aimed at evaluating lymphatic drainage as a complementary form of treatment in an elderly patient with dermatofibrosis and phlebitis of the lower limb. The patient complained of pain in the post-phlebitic region. Initially three months of clinical treatment was performed using vasotonic(diosmine), anti-inflammatory and analgesic drugs and the patient was told to rest. However this treatment was not very effective. Manual and mechanical lymph drainage was associated to the clinical treatment. The results gave a significant improvement in the symptoms and the hyperpigmentation of the affected area. This study suggests that lymph drainage obtained improves the clinical of patient with dermatofibrosis, suggesting new research for more specific characterization of this approach.
Asunto(s)
Humanos , Femenino , Anciano , Edema/terapia , Fibrosis/complicaciones , Fibrosis/terapia , Flebitis/complicaciones , Flebitis/diagnóstico , Flebitis/patología , Enfermedades Linfáticas/diagnóstico , Enfermedades Linfáticas/terapiaAsunto(s)
Humanos , Adulto , Femenino , Fibrosis/diagnóstico , Fibrosis/patología , Diagnóstico Diferencial , Fibrosis/etiología , Fibrosis/terapia , PronósticoRESUMEN
Os autores fazem uma revisão sobre a infecção pelo HCV e HIV e uma discussão sobre os aspectos da co-infecção do HCV-HIV no que diz respeito à abordagem terapêutica da hepatite C, ressaltando por que, quem, quando e como tratar